ADVA launches world’s first optical transport solution with post-quantum cryptography
8.7.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched the industry’s first optical transport solution secured by post-quantum cryptography (PQC). The FSP 3000 ConnectGuard™ optical encryption solution now protects data against cyberattacks from quantum computers that could break today’s cryptographic algorithms. The quantum-safe security technology relies on a hybrid key exchange system, combining PQC algorithms with classical encryption methods. Built for crypto-agility, the solution is ready for software updates in the future, ensuring it delivers the most robust network protection now and for decades to come.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005050/en/
ADVA’s FSP 3000 ConnectGuard™ encryption solution now protects data against cyberattacks from quantum computers (Photo: Business Wire)
“Our market-first FSP 3000 quantum-safe ConnectGuard™ encryption technology answers the urgent threat posed by quantum computers and gives organizations a way to safeguard their networks before the danger materializes. Our customers’ data will be fully protected even from cybercriminals’ intent on harvesting information so that they can store it today and exploit it tomorrow,” said Christoph Glingener, CTO, ADVA. “We’re providing long-term security for data in motion. What’s more, our solution is ready to be upgraded later to comply with emerging specifications, including the NIST’s PQC standardization competition.”
As recommended by leading cybersecurity authorities, the PQC-protected ADVA FSP 3000 ConnectGuard™ encryption solution utilizes the traditional Diffie-Hellman protocol and combines it with a newly developed algorithm based on the quantum-safe McEliece cryptosystem. This enables it to produce encryption keys that even powerful quantum computers will be unable to crack. As well as delivering data integrity with quantum-safe Layer 1 AES-256 protection, the ADVA FSP 3000 ConnectGuard™ encryption solution ensures minimal impact on latency, throughput and performance. The technology is also easily deployable over long-haul and multi-operator links.
“Organizations everywhere have woken up to the security threat that quantum computing represents. With many experts anticipating powerful commercially available quantum computers in the next decade, it’s now widely understood that the danger is very real and the stakes are enormously high. That’s why we’ve invested so much time and energy into developing the world’s first transport solution ready for the challenges ahead,” commented Jörg-Peter Elbers, SVP, advanced technology, ADVA. “By integrating PQC security into our FSP 3000 ConnectGuard™ optical encryption solution, we’re empowering our customers to protect their networks today against tomorrow’s threats. Our solution is easily deployable and only requires end-point access. What’s more, it works over any distance and in any optical transport network.”
Watch this Tech Cam video for more information: https://youtu.be/4fs6zV5FnME.
Further details are also available in these slides: https://adva.li/pqc-slides.
A supporting solution brief can be downloaded here: https://adva.li/pqc-solution-brief.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005050/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*13.11.2026 00:07:00 EET | Press release
The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience brings Percy Jackson’s adventures off the screen and into the ‘World’s Most Famous Building,’ where guests ca
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 19:09:00 EET | Press release
VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 19:00:00 EET | Press release
WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever launched. Every account represents a real person with a verified heartbeat. They have real goals, challenges, and achievements. T
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 18:00:00 EET | Press release
The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and quantum chemistry to embed safety into chemical design from the outset. Adaptive catalytic systems: Led by the Max Planck Insti
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 17:00:00 EET | Press release
Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical applications. As India continues to play a critical role in supplying medicines to patients around the world, pharmaceutical manufacturers face increasing demands for quality, regulatory compliance,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
